Guided Therapeutics, Inc.
Other OTCTotal Valuation
Guided Therapeutics, Inc. carries a market capitalization of 19.31M, placing it among publicly traded companies globally. Its enterprise value stands at 23.16M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 19.31M |
| Enterprise Value | 23.16M |
Share Statistics
Guided Therapeutics, Inc. currently has 96.51M shares outstanding.
| Shares Outstanding | 96.51M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 32.87 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | -18.03 |
| P/OCF Ratio | -18.03 |
Enterprise Valuation
| EV / Sales | 35.63 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Guided Therapeutics, Inc. maintains a current ratio of 0.37, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -145.57, indicating conservative leverage, while an interest coverage ratio of -3.06 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.37 |
| Quick Ratio | 0.09 |
| Debt / Equity | -145.57 |
| Debt / EBITDA | N/A |
| Interest Coverage | -3.06 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -523.40 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.53 |
Stock Price Statistics
Guided Therapeutics, Inc.'s stock has declined approximately -31.03448% over the past 52 weeks. The 50-day moving average sits at 0.27, while the 200-day moving average is 0.28.
| Beta (5Y) | N/A |
| 52-Week Price Change | -31.03448% |
| 50-Day Moving Average | 0.27 |
| 200-Day Moving Average | 0.28 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Guided Therapeutics, Inc. generated 650,000.00 in revenue and converted that into -2.46M in net income, yielding earnings per share of -0.03. EBITDA reached -1.42M, while operating income came in at -1.50M.
| Revenue | 650,000.00 |
| Gross Profit | 493,000.00 |
| Operating Income | -1.50M |
| Pretax Income | -2.46M |
| Net Income | -2.46M |
| EBITDA | -1.42M |
| EBIT | -1.50M |
| Earnings Per Share (EPS) | -0.03 |
Cash Flow
Guided Therapeutics, Inc. produced -1.18M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.18M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.18M |
| FCF Per Share | -0.01 |
Margins
Guided Therapeutics, Inc. operates with a gross margin of 75.85, reflecting its pricing power and cost economics. The operating margin of -230.31 and net profit margin of -378.46 provide insight into operational efficiency.
| Gross Margin | 75.85 |
| Operating Margin | -230.31 |
| Pretax Margin | -378.46 |
| Profit Margin | -378.46 |
| EBITDA Margin | -218.15 |
Dividends & Yields
The company's payout ratio of 2.77 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 2.77 |
| Shareholder Yield | -5.92 |
| FCF Yield | -5.55 |
Stock Splits
Guided Therapeutics, Inc.'s most recent stock split took place on March 29, 2019 with a 800:1 split ratio.
| Last Split Date | 3/29/2019 |
| Split Ratio | 800:1 |
Scores
Guided Therapeutics, Inc. posts an Altman Z-Score of -572.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -572.11 |